US 11464830
Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
granted A61KA61K38/1709A61K38/1793
Quick answer
US patent 11464830 (Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K38/1709, A61K38/1793, A61K38/2006, A61K39/395